¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"antibody response"¿¡ ´ëÇÑ ´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
pleiotypic response
´Ù¸é ´ëÀÀ(ÒýØüÓßëë)
primary immune response
ÀÏÂ÷ ¸é¿ª´ëÀÀ(ìéóØóæ¹Óßëë)
primary response
ÀÏÂ÷ ´ëÀÀ(ìéóÓßëë)
SOS response
SOS ´ëÀÀ(Óßëë)
staircase response
°è´Ü ´ëÀÀ(ÍÓ«Óßëë)
stringent response
¾ö°Ý ´ëÀÀ(åñÌ«Óßëë)
tertiary response
»ïÂ÷´ëÀÀ (ß²óÓßëë)
acquired antibody
"ȹµæÇ×ü (üòÔðù÷ô÷), ÈÄõ¼ºÇ×ü (ýô¸àõù÷ô÷)"
agglutinating antibody
ÀÀÁýÇ×ü(ëêó¢ù÷ô÷)
anti-idiotype antibody
Ç×(ù÷)À̵ð¿ÀŸÀÌÇÁ Ç×ü(ù÷ô÷)
anti-immunoglobulin antibody
Ç׸鿪(ù÷Øóæ¹)±Û·ÎºÒ¸° Ç×ü(ù÷ô÷)
antibody
Ç×ü(ù÷ô÷)
antibody binding fraction
Ç×ü°áÇÕºÐȹ (ù÷ô÷Ì¿ùêÝÂüò)
antibody combining site
Ç×ü°áÂø(ù÷ô÷Ì¿ó·)ÀÚ¸®
antibody dependent cellular cytotoxicity
Ç×üÀÇÁ¸ÀÚ¸® ¼¼Æ÷¼º¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øààõá¬øàÔ¸àõ)
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½